Determine the Efficacy of TT-173. Reducing the the Total Blood Loss Associated With Total Knee Arthroplasty (HESTAT)

Inclusion Criteria

• •1. Patients who signed the informed consent.
• •2. Patients affected of degenerative osteoarthritis of the knee that have to undergo a primary total knee replacement.
• •3. Patients of both sexes older than 18 years.
• •4. Female patients in childbearing age\* that are not permanently sterile, should present a negative pregnancy test and should agree to use a medically accepted anti contraceptive method during its participation in the study. This includes oral, intravaginal, transdermal, injectable or implantable hormonal contraceptives, sexual abstinence, bilateral tubal occlusion, intrauterine hormone-releasing system or dispositive and vasectomy of the partner.
• •\* Includes the period between menarche and until becoming post-menopausal. A woman is considered post-menopausal when she has gone without a period for 12 consecutive months.
• •5. Patients must have a haemoglobin concentration ≥ to 12.5 g/dL at the selection visit.
• •9. Subjects who have received treatment (erythropoietin, iron, folate) to improve preoperative anaemia.
• •10. Subjects who are not free to give informed consent or who are mentally incapacitated to the discretion of investigators.
• •11. Subjects who participate or have participated in the past three months in another clinical trial with drug treatment.
• •12. Subjects that are the investigators, collaborators, nurses, centre employees or any other person directly related to the development of the protocol.
• •13. Subjects who are pregnant or lactating.